Use of prohibitin RNA in treatment of cancer

Details Use of prohibitin RNA in treatment of cancer Use of prohibitin RNA in treatment of cancer

2007-09-25

2007-09-25

Kaushal, Sumesh (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093100, C424S093200, C435S320100, C435S325000, C435S455000, C536S023100, C536S023500

Reexamination Certificate

active

10190942

ABSTRACT:
It has now been found that the introduction of single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3′UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been observed following direct administration of prohibitin 3′UTR RNA. Induction of systemic immunity, as evidenced by the disappearance of metastases as well as the lack of tumor growth in rechallenged animals following prohibitin RNA therapy, has been observed. Thus, wild type RNAs transcribed from portions of a prohibitin 3′UTR, or single stranded DNAs comprised of portions of a prohibitin 3′UTR, or synthetically-made oligonucleotides of the same sequences, can be directly administered as therapeutic agents against tumors.

REFERENCES:
patent: 5658792 (1997-08-01), Nuell et al.
patent: 5776738 (1998-07-01), Dell'Orco, Sr. et al.
patent: 5922852 (1999-07-01), Dell'Orco, Sr. et al.
patent: WO96/40919 (1996-12-01), None
patent: WO98/20167 (1998-05-01), None
patent: WO99/24614 (1999-05-01), None
Kelloff et al, Eur. J. Cancer. 35(14):2031-2035, 1999.
Gomez-Navarro et al, Eur. J. Cancer. 35(6);867-885, 1999.
Mastrangelo et al, Semin. in Oncology. 23(1): 4-21, 1996.
Campbell et al, Cancer Epidemiol. Biomarkers Prev.12:1273-1274, 2003.
Stegmann et al. Biochem. Biophy. Acta. 1325:71-79, 1997.
PTO-Sequence Search Report for WO 96/40919, conducted 052404.
PTO-Sequence Search Report for US 5,922,852, conducted 052404.
New England Biolabs, Catalog 1988-1998, Product # 1230.
Manjeshwar et al, J. Mol. Hist. 35:639-646, 2004.
Manjeshwar et al, Cancer Res. 63:5251-5256, 2003.
Jupe et al., “Prohibitin antiproliferative activity and a lack of heterozygosity in immortalized cell lines,”Exp Cell Res,218:577-580, 1995.
Jupe et al., “Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3′ untranslated region mutations,”Cell Growth and Differentiation,7:871-878, 1996.
Jupe et al., “The 3′ untranslated region of prohibitin and cellular immortalization,”Exp Cell Res,224:128-135, 1996.
McClung et al., “Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver,”Biochem Bioophys Res Comm,164:1316-1322, 1989.
Nagai et al., “Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumors,”Genes, Chromosomes, and Cancer,11:58-62, 1994.
Nuell et al., “Prohibitin, an evoluntionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells,”Mol Cell Bio,11:1372-1381, 1991.
Wang et al., Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function,Oncogene,18:3501-3510, 1999.
White et al., “Assignment of the human prohibitin gene (PHB) to Chromosome 17 and identification of a DNA polymorphism,”Genomics,11:228-230, 1991.
Jupe et al., The prohibition of 3′UTR as a susceptibility marker and therapeutic in breast cancer,Proceedings of the American Association for Cancer Research,40:481, 1999 (Abstract #3175).

Affiliated with

Also associated with

Rating

Use of prohibitin RNA in treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of prohibitin RNA in treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of prohibitin RNA in treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3720885